Alentis Therapeutics, AG announced it has dosed the first cohort of healthy participants in a first-in-human Phase 1 clinical trial of ALE.F02, a monoclonal antibody highly selective for Claudin-1, currently being developed for the treatment of advanced unmet liver and kidney fibrosis. Alentis is a clinical stage biopharma focused on discovering and developing novel therapies… Continue reading Alentis Therapeutics Starts First-in-Human Clinical Trial for the Treatment of Liver and Kidney Fibrosis
Category: Healthcare
Read Magazine provides latest news and granular market insights from the Healthcare, Surgical, Wellness, Devices, and allied domains.
Core xRM Acquires WeCare
Core xRM, an innovative healthcare technology company whose products support healthcare payers with operationally essential technology including Software as a Service ‘SaaS’, data management and data quality solutions, announced its acquisition of WeCare, a technology company focused on improving outcomes for healthcare consumers in the United States. WeCare’s passion focuses on bringing improved consumerism to… Continue reading Core xRM Acquires WeCare
Novavax Submits Final Data Packages to U.S. FDA as Prerequisite to Emergency Use Authorization Application Request for COVID-19 Vaccine
Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has completed submission of the final data package, including the complete chemistry, manufacturing and controls module, to fulfill the prerequisites for emergency use authorization (EUA) application request to the U.S. Food and Drug Administration (FDA)… Continue reading Novavax Submits Final Data Packages to U.S. FDA as Prerequisite to Emergency Use Authorization Application Request for COVID-19 Vaccine
Antengene Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors
Antengene Corporation Limited, a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer and other life-threatening diseases, announced today that the first patient has been dosed in the Phase Ib/II, open-label multi-center, REACH trial to evaluate ATG-016 (eltanexor) monotherapy in subjects with advanced solid tumors including those… Continue reading Antengene Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors
PharmAbcine Announces First Patient Enrolled and Dosed in the Phase II Clinical Trial for the Treatment of mTNBC
PharmAbcine Inc., a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced it has dosed the first patient in its Phase II clinical trial evaluating the combination of olinvacimab, PharmAbcine‘s anti-VEGFR2 (Vascular Endothelial Growth Factor Receptors) antibody, and KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 molecule, for the treatment of mTNBC (metastatic Triple-Negative Breast… Continue reading PharmAbcine Announces First Patient Enrolled and Dosed in the Phase II Clinical Trial for the Treatment of mTNBC
EOFlow and Zihipp Announce Joint Venture for Development of Innovative Solutions for Treatment of Obesity & NASH
EOFlow Co., Ltd., a provider of wearable drug delivery solutions, has announced that its wholly owned US subsidiary, EOFlow Inc. has signed an agreement to establish a joint venture in the US with the UK biotech firm Zihipp Limited, a spin out from Imperial College London. Also Read: Kolon Tissuegene Resumes TG-C Phase III Studies… Continue reading EOFlow and Zihipp Announce Joint Venture for Development of Innovative Solutions for Treatment of Obesity & NASH
Kolon Tissuegene Resumes TG-C Phase III Studies in the US
Kolon TissueGene, Inc., a leader in advanced cell and gene therapies, announced that it has resumed patient dosing in its U.S. Phase III study of TG-C for the treatment of knee osteoarthritis (OA). Also Read: Soin Therapeutics Completes Formulation Development of Novel Low Dose Naltrexone Tablet to Treat Complex Regional Pain Syndrome The two pivotal… Continue reading Kolon Tissuegene Resumes TG-C Phase III Studies in the US
Soin Therapeutics Completes Formulation Development of Novel Low Dose Naltrexone Tablet to Treat Complex Regional Pain Syndrome
Soin Therapeutics, a biotechnology company based in Dayton, OH, has completed the formulation development work of their novel, proprietary low dose naltrexone pill to treat Complex Regional Pain Syndrome (CRPS). CRPS is a debilitating, orphan disease characterized by severe chronic pain, swelling, and hypersensitivity to touch- among other undesirable symptoms which typically affects the upper… Continue reading Soin Therapeutics Completes Formulation Development of Novel Low Dose Naltrexone Tablet to Treat Complex Regional Pain Syndrome
WuXi Biologics and ImmuneOncia Sign MOU for Development and Manufacturing of Anti-PD-L1/CD47 Bispecific Antibody
WuXi Biologics, a global company with leading open-access biologics technology platforms, and ImmuneOncia Therapeutics, Inc., a clinical-stage, immuno-oncology company in South Korea, announced that a Memorandum of Understanding (MOU) was signed to form a strategic partnership in the development and manufacturing of IOH-001, ImmuneOncia’s therapeutic bispecific antibody targeting PD-L1 and CD47. Also Read: Relmada Therapeutics… Continue reading WuXi Biologics and ImmuneOncia Sign MOU for Development and Manufacturing of Anti-PD-L1/CD47 Bispecific Antibody
Smart Meter Announces Partnership With A&D Medical
Smart Meter, the leader in cellular-enabled remote patient monitoring (RPM) data and devices, announced a partnership with A&D Medical, a global leader in connected health and biometric measurement devices and services. Through this partnership, Smart Meter and A&D Medical will develop and deliver top-quality RPM devices that use advanced cellular-enabled technology to best connect patients,… Continue reading Smart Meter Announces Partnership With A&D Medical